Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2
about
Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transportersRole of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceThe pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapyVandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport functionThe phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporterBIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cellsDeterminants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478Markers of tumor-initiating cells predict chemoresistance in breast cancer.ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expressionAnthracenedione derivatives as anticancer agents isolated from secondary metabolites of the mangrove endophytic fungiARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2.Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.Metabolism considerations for kinase inhibitors in cancer treatmentAxitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma.Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function.Retrovirus-mediated multidrug resistance gene (MDR1) overexpression inhibits chemotherapy-induced toxicity of granulosa cells.Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceSildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1.The challenge of exploiting ABCG2 in the clinic.WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells.Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters.ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Urothelial carcinomas: a focus on human epidermal receptors signalingDichloroacetate restores drug sensitivity in paclitaxel-resistant cells by inducing citric acid accumulation.The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study.Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation.An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team upDiscovering natural product modulators to overcome multidrug resistance in cancer chemotherapy.
P2860
Q24617999-82D2FEDF-0C41-42A3-B627-1F49C4BCE314Q26865927-B7766519-BDA3-4608-9D63-86AD9B7740C9Q27004672-51D43430-29FA-4106-95CC-8118817BF965Q28475378-BE39B503-2671-438F-B42F-47E194660E58Q28477938-875F1F31-21E1-4F21-850C-91566B6AD6BBQ28485188-2D6E73F5-D79D-46E1-9D9A-A0A1DFE54BB4Q30364846-E08FE503-0B23-4068-A388-9917FA3328C2Q30438089-1F9A695B-591A-4A23-9605-8A7ED2B648D8Q33511437-9E093D01-09EC-4C99-A5F5-4B7F10554BF3Q33533700-794D887D-EF66-4B07-8365-B1C739B8D376Q33633267-E165E25F-4DCF-4E84-ADDF-4365E2B0B007Q33746958-B94BEC79-8E23-4805-B186-FA8C3CCEB6E5Q33781163-FC84516E-85D6-4F15-A3C7-4152F2169490Q33829405-261D4452-45C9-4807-A2B1-2334EB55BF00Q33837067-3F69C6D6-0436-4A3C-9F43-DA9D6D51FCC8Q33861296-842AF6D0-7054-4929-B5C3-966F21A46F44Q34046157-C96BC493-C986-4E18-BCCB-DFC634F5EF97Q34048144-02B8EFC3-024A-4D0F-AE03-DFAA85584A60Q34134390-A9C79E25-F583-4241-BF6E-D3750DA8B189Q34253081-0E152B99-C1A1-438F-876D-E0675E9BAD0BQ34414027-6A3389A3-A34E-4920-9BE8-4E7C98543210Q34416223-F25DD4A9-1F63-439F-AA17-E0AEF3F4D83FQ34726096-FC9D10D9-46AF-493C-BD6D-8EA381C55E9EQ34774854-7E0378D0-B1B6-464C-86AA-E6740D57BB85Q34803651-AB4A06FB-2D21-4F78-A689-59B68175E411Q34871636-9F63CA19-8F45-4294-9AB5-3251DB87921AQ34914312-A389E3C7-F019-4B3E-87DD-5359136A0F70Q34968909-43F96DEF-9759-4E5C-8515-0546F272917FQ35051599-C99C4226-D2B3-4D27-AF6D-CC745056EDDAQ35067898-F166D757-0BDD-4A43-ACFE-B5F3769A4DC3Q35141800-8E0C5FB2-C9E8-43F5-9161-BD2D1C241C8DQ35171274-1F7393F7-62B3-4E1B-A3EA-44F077B5C24AQ35172558-1B455DE2-00E0-47E9-8F46-4A439134DAF8Q35232780-9175038B-C658-4CAA-A14F-FC79127D2864Q35238509-94769880-9FF7-4C4C-A8F6-0B841D23BA72Q35284749-E222825A-6855-473C-84C3-DF6381DBED44Q35623065-F440DD1B-EA36-4598-80B8-2B548AFC1E43Q35708124-8D316D17-4285-4B20-B5A3-B35FE9D381EAQ35720625-0540A619-9619-4370-9349-3C7B5E4C50EEQ35915497-B77300B5-DF8D-46A1-B411-DF0BB3E22156
P2860
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lapatinib (Tykerb, GW572016) r ...... mily B member 1 and G member 2
@en
Lapatinib (Tykerb, GW572016) r ...... ily B member 1 and G member 2.
@nl
type
label
Lapatinib (Tykerb, GW572016) r ...... mily B member 1 and G member 2
@en
Lapatinib (Tykerb, GW572016) r ...... ily B member 1 and G member 2.
@nl
prefLabel
Lapatinib (Tykerb, GW572016) r ...... mily B member 1 and G member 2
@en
Lapatinib (Tykerb, GW572016) r ...... ily B member 1 and G member 2.
@nl
P2093
P2860
P50
P1433
P1476
Lapatinib (Tykerb, GW572016) r ...... mily B member 1 and G member 2
@en
P2093
Charles R Ashby
Cheng-Jun Shi
Chun-ling Dai
Chung-Pu Wu
Dong-geng Liu
Li-ming Chen
Si-Rong Wang
Suresh V Ambudkar
Xiao-Dong Su
P2860
P304
P356
10.1158/0008-5472.CAN-08-0499
P407
P577
2008-10-01T00:00:00Z